Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL056 vs Alendronate in Postmenopausal Osteoporosis
NCT07028320Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of Xinfutai in postmenopausal osteoporosis, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Dec 2021; status: completed.
02
Drugs
Xinfutai
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT07028320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028320.